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Multiple sclerosis (MS) is an inﬂammatory demyelinating, presumably autoimmune disease of the central nervous system (CNS).
Among the available MS therapies, interferon (IFN)β and the recently introduced statins have been reported to exert their
immunomodulatory eﬀects through the induction of SOCS1 and SOCS3 in various inﬂammatory cell subsets. The SOCS proteins
negatively regulate cytokine and Toll-like receptors- (TLR-) induced signaling in the inﬂammatory cells. SOCS1 and SOCS3 have
been reported to play an important role in the regulation of Th17-cell diﬀerentiation through their eﬀects on the cells of the innate
and adaptive immune systems. IFNβ and statins inhibit Th17-cell diﬀerentiation directly and indirectly via induction of SOCS1
and SOCS3 expression in monocytes, dendritic cells (DCs), and B-cells. Due to their rapid induction and degradation, and SOCS-
mediated regulation of multiple cytokine-signaling pathways, they represent an attractive therapeutic target in the autoimmune
diseases, and particularly relapsing remitting (RR) MS.
1.Introduction
MS is a chronic progressive CNS inﬂammatory disease, in
which the autoimmune response against the CNS myelin
proteins leads to a chronic inﬂammatory response [1, 2].
During the inﬂammatory response, autoreactive T-cells mi-
grate through the otherwise impermeable blood-brain bar-
rier into the CNS perivascular areas, where they cause de-
myelination and axonal degeneration. The chronic inﬂam-
matory response leads to neuronal conduction deﬁcits asso-
ciated with neurological symptoms and eventually results in
the loss of functional neuronal tissue. Several immunomod-
ulatory and immunosuppressive therapies (IFNβ, glatiramer
acetate, ﬁngolimod, natalizumab, and mitoxantrone) are
used in clinical practice as eﬀective therapies in controlling
diseaseactivityanddisabilityprogressioninpatientswithRR
MS.
T h 1 7 - c e l l sh a v eb e e ns h o w nt op l a yac r i t i c a lr o l ei nt h e
development of autoimmune responses in several autoim-
mune diseases, including MS, rheumatoid arthritis, psori-
asis, juvenile diabetes, ulcerative colitis, and autoimmune
uveitis [3, 4]. Th17-cells are identiﬁed in the CNS MS
lesions, cerebrospinal ﬂuid, and among the blood-derived
mononuclear cells from MS patients, implying that they
may play a critical role in the immunopathogenesis of MS
[5–8]. Our laboratory has identiﬁed increased numbers
of Th17-cells and an increase in the Th17-cells’ master
regulatory transcription factor, retinoic acid-related orphan
nuclear factor (RORc), and cytokines that mediate Th17-
cell expansion [8] in MS lesions. Th17-cell frequency is
approximately 7 times higher in the peripheral circulation
of RR MS patients in comparison to healthy controls (HCs),
and it positively correlates with the clinical disease activity
[9]. While multiple studies have reported on the association
of Th17-cells and autoimmune diseases, only several reports2 Journal of Signal Transduction
have provided a mechanistic data on the function of IL-
17A in the development of the autoimmune response. IL-
17AinducesthesecretionofCXCL1andCXCL2,neutrophil-
attracting cytokines, which attract those inﬂammatory cells
into the CNS in the early or acute phase of the disease
[10]. IL-17A together with IL-22 induces blood brain barrier
permeability due to their eﬀect on the endothelial cells [11].
IL-17A induces production of additional proinﬂammatory
cytokines, including IL-1 and IL-6 [12], and cytokines
coexpressed by Th17-cells, IL-9, IL-21, IL-22, and GM-
CSF, also contribute to the development of the autoimmune
response.
SOCS proteins are a family of intracellular cytokine-
inducible proteins, consisting of 8 members (CIS and
SOCS1-SOCS7). They have two structural components: an
Src homology domain (SH2), which is involved in phos-
photyrosine binding to activated signaling molecules and a
C-terminal SOCS box involved in the degradation of sig-
nalingmoleculesthroughtheubiquitin-proteasomepathway
[13]. SOCS gene expression is triggered by interleukins,
interferons, haematopoietic growth factors, and TLR ligands
suchaslipopolysaccharides(LPS)andCPG-containingDNA
[13, 14]. The induction of the SOCS proteins occurs through
cytokine-mediated activation of the Janus kinase/signal
transducers and activators of the transcription (JAK/STAT)
signaling pathway, which leads to the phosphorylation of the
STAT transcription factors. The SOCS proteins negatively
regulate cytokine signaling through their association with
phosphorylated tyrosine residues on JAK proteins and/or
cytokine receptors or by inhibition of STAT binding to the
cytoplasmic domain of the receptors. They terminate the
inﬂammatory responses by mediating proteasomal degrada-
tion of the bound proteins [13, 15, 16]. Among the SOCS
family members, SOCS1 and SOCS3 have been described
to play the most important role in the regulation of the
autoimmune response. They are rapidly induced and de-
graded. They block phosphorylation-dependent activation
o fS T A T 1i nr e s p o n s et oI F N - γ, or STAT3 in response to IL-
6, and target the IFNγR- and IL-6R-signaling complexes for
proteasomal degradation [17]. Interestingly, two recent large
genetic studies have identiﬁed SOCS1 as one of the genes
with the strongest association with the susceptibility for MS
[18, 19].
Among the available MS therapies, IFNβ and the re-
cently introduced statins have been reported to exert their
immunomodulatory eﬀects through the induction of SOCS1
and SOCS3 in various inﬂammatory cell subsets. IFNβ and
statins inhibit Th17-cell diﬀerentiation directly and indirectly
via their eﬀects on antigen-presenting cells (APCs). In this
paper, we will discuss their therapeutic eﬀects in RR MS
patients, which are indirectly mediated through the induc-
tion of SOCS1 and SOCS3 in monocytes, DCs, and B-cells as
well as directly aﬀecting the Th17-cells.
2. Th17-Cell Differentiation
Similar to Th1- and Th2-cells, the diﬀerentiation of Th17-
cells is orchestrated by cytokines secreted by APCs. The
diﬀerentiation of mouse and human Th1-cells occurs upon
exposure to IL-12 and IFN-γ and Th2-cells upon exposure
to IL-4 and IL-10, whereas the diﬀerentiation of mouse and
human Th17-cells diﬀer in the required Th17-polarizing
cytokines [20, 21]. TGF-β and IL-6 are required in the
mouse, while IL-6, IL-1β, and IL-23 drive human Th17-
cell diﬀerentiation [22–24]. Speciﬁc STAT molecules are
involved in the diﬀerentiation of each T-cell subset. Th1-
cells’ diﬀerentiation induced by IFN-γ and IL-12 mediate
activation of STAT4 and STAT1, which directly control the
transcription factor T-bet. In the diﬀerentiation of Th2-
cells, IL-4-induced STAT6 phosphorylation is crucial for the
gene transcription of the master regulatory transcription
factor GATA-3 [25], whereas STAT3 is pivotal in human and
mouse Th17-cell diﬀerentiation, where it is induced by IL-
6, IL-23, and IL-21 [26] .T h e s es t u d i e sh a v ed e m o n s t r a t e d
a pivotal role of STAT molecules in T-cell diﬀerentiation.
STATs’ regulation is critical for the cytokine secretion proﬁle
and the subsequent inﬂammatory T-cell responses.
3.The Role of SOCS1 in
the Inﬂammatory Response
SOCS1 is induced by various cytokines, including IFNβ,
IFNγ, IL-4, and IL-6 [27, 28], which activate the Jak/STAT
signaling pathway. Several studies have demonstrated that
SOCS1 is induced by the TLR4 (LPS) and TLR9 ligands
(CPG-DNA) [14, 29]. SOCS1 classically inhibits IFN signal-
ing through association with the IFN-α receptor 1 (IFNAR1)
and IFN-γ receptor (IFNGR) subunits and suppression of
IFN-induced STAT1 and STAT3 phosphorylation [30–32].
In addition to IFN regulation, SOCS1 also inhibits TNF-α
signaling [14, 29]. SOCS1 deﬁciency leads to overrespon-
siveness to IFN-γ, whereas SOCS1 overexpression leads to
a reduced responsiveness to IFN-γ in various cell subsets
[31, 33, 34], implying that SOCS1 plays a negative regulatory
role in IFN-γ signaling.
4.SOCS3 Regulates CytokineSignaling
SOCS3 is expressed in DCs, monocytes, T-cells and B-cells
upon induction by IL-2, IL-3, IL-6, IL-12, IL-23, IFNα/β/γ,
IL-27, IL-4, IL-10, IL-1, TGFβ,T N F - α, GM-CSF, and LPS.
SOCS3 expression is high in resting CD4 cells, but it rapidly
decreases after T-cell receptor activation. Earlier studies
have reported that during T-cell diﬀerentiation, SOCS3 is
selectively expressed in Th2-cells, while SOCS1 expression
is higher in Th1-cells. High SOCS3 expression in transgenic
mice led to skewing to Th2 type diﬀerentiation, because
SOCS3 binds to IL-12RB2 and inhibits the IL-12-mediated
STAT4 activation, therefore blocking Th1-cell development
[35]. SOCS3 inhibits IL-6 signaling by binding to the IL-
6 gp130 receptor complex and mediating its proteasomal
degradation [36, 37]. The expression of SOCS3 nega-
tively regulates STAT1 and STAT3 phosphorylation. During
Th17-cell diﬀerentiation, STAT3 induces the expression of
the master regulatory transcription factor RORc and is,
therefore, critical for the diﬀerentiation of human and
mouse Th17-cells [26, 38, 39]. The suppression of STAT3
phosphorylation is an eﬀective mechanism for suppressingJournal of Signal Transduction 3
Th17-cell diﬀerentiation. A SOCS3 deﬁciency in na¨ ıve T-
cells leads to a sustained STAT3 phosphorylation and results
in higher frequencies of diﬀerentiated Th17-cells [40]. In
addition, SOCS3 deﬁciency in T-cells is associated with
enhanced IL-17A production, induced by IL-23 or IL-6
plus TGF-β [40]. IL-27 signaling can also induce SOCS3
via STAT1 so that IL-27 may block Th17-cell development,
as may type I and II IFNs, via sequential activation of
STAT1 and SOCS3, resulting in STAT3 antagonism [41].
Monocytes, CD4+ and CD8+ T - c e l l sw e r ef o u n dt oh a v ea
lower SOCS3 and increased STAT3 expression during MS
relapses [42]. Furthermore, SOCS3 suppresses the Th17-
polarizing cytokine IL-1β and IL-23 secretion by DCs and B-
cells [43, 44]. SOCS3 is induced by several stimuli in APCs,
where it plays an important role in the inhibition of Th17
polarizing cytokines IL-1β and IL-23, which suppress STAT3
activation required for the gene transcription of the master
Th17cellregulatorytranscriptionfactorRORc.Thesestudies
suggest that SOCS3 induction may represent a beneﬁcial
therapeutic approach in patients with RR MS.
5. The Role of IFNβ-InducedSOCS
Expressionin the Treatment of RR MS
IFNβ is an innate immune response cytokine that sup-
presses the disease activity and disability progression of
RR MS and its animal model, experimental autoimmune
encephalomyelitis(EAE).Earlierstudiesinmiceandhumans
have demonstrated an association between an endogenous
IFNβ deﬁciency and an increased susceptibility for EAE
and RR MS [45, 46]. In addition, the administration of
exogenous IFNβ eﬀectively reduced the clinical relapse rate
and the formation of new CNS lesions in several large
placebo-controlled clinical trials [47]. An increase in the
Th1 receptor IL-12Rβ2 expression and the secretion of the
immunoregulatory cytokine IL-10 [48, 49] were identiﬁed
as the biomarkers of IFNβ’s therapeutic eﬀects. Multiple
proposed mechanisms of IFNβ’s therapeutic eﬀect include
inhibition of antigen presentation, suppression of T-cell
proliferation and migration, and modulation of proinﬂam-
matory cytokine production [48, 49]. More recent studies
have shown that IFNβ eﬀectively suppresses Th17-cells
diﬀerentiation in mouse and human. Mice deﬁcient for
IFNAR1 receptor and its downstream signaling molecules
have been found to be more susceptible to EAE [50, 51]. In
addition, Durelli et al. have demonstrated that IFNβ reduced
the numbers of Th17-cells in their longitudinal study of
IFNβ-1a-treated RR MS patients [9]. This ﬁnding has been
supported by our in vitro experiments on the eﬀect of IFNβ
on human Th17-cell diﬀerentiation, where we demonstrated
that IFNβ suppresses Th17-cell diﬀerentiation via its eﬀects
on monocytes, DCs, B-cells and na¨ ıve T-cells [43, 44, 52].
Monocytes, macrophages, DCs and B-cells induce
human Th17-cell diﬀerentiation through their secretion
of IL-1β and IL-23. Li et al. have reported an increased
expression of IL-23p19 in acute MS brain lesions, while
Vaknin-Dembinsky et al. identiﬁed an increased synthesis
of IL-23 by DCs derived from MS patients [53, 54]. In
our in vitro experiments, we found a decreased expression
of IL-1β and IL-23, whereas IL-12p35 and IL-27 gene
expression was increased in IFNβ-treated DCs [54]. RR
MS patients treated with IFNβ have been reported to have
reduced IL-23p19 gene expression in their peripheral blood
mononuclear cells (PBMCs) [49], a ﬁnding that is reinforced
by our in vitro experiments showing that DCs and B-cells
exhibited decreased IL-23 secretion upon incubation with
IFNβ [43, 44, 52]. We also demonstrated that the reduced
secretion of IL-1β and IL-23 in supernatants (SNs) from
IFNβ-treated DCs led to a decreased diﬀerentiation of Th17-
cells. The addition of IL-1β and IL-23 and the blocking of
IL-27 in the SNs from IFNβ-treated DCs and B-cells lead
to a reversal of the IFNβ eﬀect and an increase in Th17-cell
diﬀerentiation [43, 44]. In IFNAR knock-out mice that are
highly susceptible to EAE, the EAE is reversed with IL-27
administration [51]. These studies led us to conclude that
IFNβ suppresses the Th17-cell diﬀerentiation by inhibiting
IL-1β and IL-23 and inducing IL-27 secretion in DCs and B-
cells as shown in Figure 1.
IFNβ is a potent inducer of SOCS1 and SOCS3, molecu-
les that contribute to Th17-cell diﬀerentiation [43, 55, 56].
We observed an increased expression of SOCS3 in IFNβ-
treated DCs, which is induced through STAT3 activation [43,
44]. Several studies have reported that SOCS3 suppresses IL-
1β and IL-23 expression [57, 58]. Collectively, these reported
invitroandinvivo ﬁndingsindicatethatIFNβ suppressesthe
IL-1β and IL-23 expression through SOCS3 upregulation in
DCs and B-cells [43, 44].
We found that B-cells from RR MS patients and HCs
exhibit an increased SOCS1 expression upon IFNβ-induced
STAT1phosphorylation[44].In vivo studiesbyLiuetal.have
demonstrated that IFNβ-1b treatment of RR MS patients
inhibits the CD40 co-stimulatory molecule expression on B-
cells[59].WefurtheridentiﬁedinourexperimentsthatIFNβ
inhibited CD40 expression on B-cells through the induction
of SOCS1 [44]. STAT1 phosporylation is required for SOCS1
expression, which negatively regulates CD40 expression.
STAT1 inhibition with ﬂudarabine leads to increased CD40
expression in B-cells and the reversal of IFNβ-1b’s in-vitro
eﬀect [44, 55]. Similar ﬁndings have been reported for the




and subsequently on their antigen presenting capacity [44].
The T-cell proliferation decreased when IFNβ-pretreated B-
cells were used as APCs and cocultured with the antigen-
speciﬁc T-cells. In contrast, the proliferative response was
reversed when the IFNβ-treated B-cells were simultaneously
incubated with the STAT1 inhibitor ﬂudarabine. These
results conﬁrm the role of IFNβ-1b-induced STAT1 phos-
phorylation and SOCS1 expression in the inhibition of the
antigen presenting capacity of B-cells.
In a recent study, Tanaka et al. have demonstrated that
the EAE induction was reduced in mice with a T-cell-speciﬁc
SOCS1 knockout [56], which diﬀerentiated into Th1-cells,
while the frequency of Th17-cells was reduced. The SOCS1-
deﬁcient T-cells exhibited a sustained STAT1 activation [56].



















(macrophages, DCs, andB cells)
Na¨ ıve CD45RA+ cells
Figure 1: IFNβ and simvastatin induce expression of SOCS1 and SOCS3. IFNβ induces the phosphorylation of STAT1 and STAT3. STAT3
phosphorylation leads to the induction of SOCS3 expression, which downregulates the expression of IL-23 and IL-1β. The cytokines
IL-23 and IL-1β promote the development of Th17-cells. In B-cells, the induction of STAT1 results in the expression of SOCS1, which
downregulatesthecostimulatorymoleculeCD40.IFNβ alsoactsonna¨ ıveCD45RAbyinducingSTAT1phosphorylation,whichsubsequently
induces SOCS3 that suppresses the STAT3 activation responsible for RORc gene transcription. Simvastatin induces the phosphorylation of
STAT3 in APCs that leads to the expression of SOCS3, which in turn inhibits the gene transcription of IL-1β and IL-23.
signaling, na¨ ıve T-cells were overresponsive to IFN-γ [56]
and preferentially diﬀerentiated into a Th1-cell phenotype.
Not all RR MS patients respond to IFNβ therapy,
and early identiﬁcation of nonresponders is important to
avoid irreversible disability progression. Comabella et al.
have recently demonstrated that monocytes from RR MS
nonresponders have an increased baseline level of STAT1
phosphorylationandIFNAR1expressioncomparedtoIFNβ-
responders, which are identiﬁed by the suppression of
clinicaldiseaseactivity.Inaddition,nonrespondersproduced
increased levels of endogenous IFNβ [61]. However, the
expression of SOCS1 and SOCS3 was similar in responders
and non-responders, suggesting that these negative regula-
t o r so fS T A T 1a c t i v a t i o nm a yb ee x p r e s s e db u tf u n c t i o n a l l y
deﬁcient in non-responders.
In summary, IFNβ induces the SOCS1 and SOCS3
protein expression in APCs. The induction of SOCS1 in
B-cells leads to CD40 suppression, whereas the induction
of SOCS3 inhibits the gene expression of Th17-polarizing
cytokines IL-1β and IL-23. In na¨ ıve CD45RA T-cells, IFNβ
also induces SOCS3 which inhibits STAT3 cell signaling and




Statins are selective inhibitors of 3-hydroxy-3-methylglutaryl
(HMG)-CoA reductase, an enzyme involved in the conver-
sion of HMG-CoA to mevalonic acid. Statins have been
widely used as cholesterol-lowering agents in the treatment
of cardiovascular diseases. More recently, they have been
found to have anti-inﬂammatory and immunomodulatory
properties, since they inhibit DCs’ maturation and antigen
presentation [62, 63]. The anti-inﬂammatory beneﬁts of
statins are related to their ability to reduce mevalonate and
the mevalonate-derived isoprenoids farnesyl pyrophosphate
(FPP) and geranylgeranyl pyrophosphate (GGPP). FPP and
GGPP are involved in the posttranslational modiﬁcation
of small G-proteins. Simvastatin may have a therapeutic
potential in RR MS [64], since it has been demonstrated
to decrease new CNS lesion formation by 42% after six
months of treatment in comparison to the baseline magnetic
resonance imaging studies [65]. Statins’ immunotherapeutic
mechanisms of action are currently not fully understood.
We have also reported that na¨ ıve CD45RA+ T-cells
cultured with SNs from simvastatin-treated monocytesJournal of Signal Transduction 5
decreased Th17-cell diﬀerentiation. The simvastatin treat-
ment of monocytes and DCs from RR MS patients and
HC induced decreased expression of the Th17-promoting
cytokines IL-1β and IL-23 [66, 67]. We have also identiﬁed
an increase in the SOCS3 expression in simvastatin-treated
monocytes [68, 69]. Statin-induced SOCS3 downregulates
the expression of IL-1β and IL-23, creating a cytokine
milieu that inhibits the Th17-cell diﬀerentiation, as shown
in Figure 1.
Previous EAE studies have indicated that statins shifted
Th1 cytokine (IFN-γ, IL-12, and TNF-α) to Th2 cytokine
production (IL-4, IL-5, and IL-10) [68]. A more recent
study has suggested that statins inhibit human Th17-cells’
diﬀerentiation and the production of the Th17 cytokines
IL-17A, IL-17F, IL-21, and IL-22 [67]. Huang et al. have
demonstrated that statins block STAT1 phosphorylation,
which is crucial in IFN-γ signaling and Th1-cell diﬀerenti-
ation [16]. SOCS3, a negative regulator of STAT1 and STAT3
activation, is increased in the statin-treated cells [66]. STAT1
phosphorylation is required for Th1 and STAT3 activation
for Th17-cell diﬀerentiation. Statin-induced SOCS3 expres-
sion is proposed to downregulate the STAT1 and STAT3
phosphorylation during Th1 and Th17-cell diﬀerentiation,
through which its therapeutic eﬀect is mediated in RR MS.
7. Conclusions
IFNβ and statins have been shown to be an eﬀective treat-
ment of RR MS. Despite diﬀerent mechanisms of action,
both therapies target similar signaling pathways. IFNβ sup-
presses the diﬀerentiation of pathogenic Th17-cells, through
its eﬀect on the cells of the innate system (macrophages,
monocytes, DCs, and B-cells), by the inhibition of the Th17-
cell-promoting cytokines IL-1β and IL-23 via induction of
SOCS3. In B-cells, IFNβ downregulates CD40 costimulatory
molecule expression through the induction of SOCS1. IFNβ
also inhibits Th17-cell diﬀerentiation directly through the
suppression of RORc.
Statins lead to SOCS3 and SOCS7 expression in the
innate immune response cells. In monocytes and DCs,
SOCS3inhibitsIL-1βandIL-23expression,whichleadstoan
inhibitory cytokine milieu for the Th17-cells’ diﬀerentiation.
Statins and IFNβ both induce the SOCS3 expression, which
is crucial in the suppression of Th17-cell diﬀerentiation and
consequently for their therapeutic eﬀect in RR MS.
The available results have identiﬁed SOCS proteins as
an attractive therapeutic target in autoimmune diseases. The
designer SOCS-mimetic drugs have already been tested in
an animal model of the CNS inﬂammatory disease. Tyrosine
kinase inhibitor peptide (Tkip), a short peptide SOCS1
mimetic, both prevented and treated active EAE [69], thus
representing a promising therapeutic approach that will
likely be further pursued in clinical testing.
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